Zoladex Gets Indication for Advanced Breast Ca

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 1
Volume 5
Issue 1

WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals' gonadotropin-releasing-hormone (GnRH) agonist, has received approval for use in the treatment of advanced breast cancer in premenopausal and perimenopausal women.

WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals'gonadotropin-releasing-hormone (GnRH) agonist, has received approvalfor use in the treatment of advanced breast cancer in premenopausaland perimenopausal women.

The agent was introduced in the United States for the treatmentof advanced prostate cancer in 1989 and for the treatment of endometriosisin 1993.

Zoladex, given by injection once a month, acts on the pituitarygland to cause decreased production of estrogen by the ovaries.This lowers serum estrogen levels to concentrations typical ofpostmenopausal women, reducing estrogen stimulation of breasttumor growth.

The new indication is based on results of clinical trials involvingmore than 800 women in North America and Europe, showing responserates and survival benefits comparable to those achieved by oophorectomy,the company said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content